Dan Horne

Dan Horne has worked in medicinal chemistry for over 13 years. Dan began their career in 2006 as a Principal Scientist at Amgen, where they were a group leader and project leader, supervising up to 5 chemists and leading project teams of up to 10 internal and 8 external chemists. Dan made significant contributions to programs in multiple therapeutic areas, including neuroscience, cardiometabolic disease, inflammation, and oncology. Dan successfully led the TRPM8 chemistry project team that produced two high-quality clinical candidates, one of which has progressed to human clinical trials (AMG 333) and the other nominated as a backup clinical candidate (AMG 399). In 2018, Dan moved to Sage Therapeutics as a Principal Scientist, Medicinal Chemistry. In 2019, they were appointed Director of Medicinal Chemistry at Skyhawk Therapeutics.

Dan Horne's education history includes a Bachelor of Science in Chemistry from UC Irvine (1994-1997), a Doctor of Philosophy in Organic Chemistry, Transition Metal Catalysis, and Natural Product Synthesis from Stanford University (1997-2004), and a PostDoctoral Research in Organic Chemistry and Natural Product Synthesis from Scripps Research (2004-2006).